P
TGTX icon

&Partners’s TG Therapeutics TGTX Stock Holding History

&Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,836
Closed -$294K – 2565
2026
Q1 		$294K Buy
+8,836
New +$263K ﹤0.01% 2009

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

&Partners's TGTX Position: Q2 2026 in Review

&Partners sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 8,836 shares — an estimated $294K sold.

&Partners first reported a position in TGTX in Q1 2026 and held it in 1 quarter. The position peaked at $294K in Q1 2026. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • &Partners reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • &Partners sold 8,836 TG Therapeutics shares in Q2 2026, an estimated $294K.
  • &Partners first reported a position in TG Therapeutics in Q1 2026 and held it in 1 quarter.
  • &Partners's TG Therapeutics position peaked at $294K in Q1 2026.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.